BOSTON–(BUSINESS WIRE)–binx healtha healthcare technology and diagnostics company is pleased to announce its selection as a finalist in the Excellence in Medical Design Award 2022. The Medical Design Excellence Awards (MDEA) are the premier awards program for the medical technology industry with a mission to recognize significant achievement in the design and engineering of medical products that improve the quality of delivery and accessibility of health care.
“We are honored to be part of the esteemed list of MDEA 2022 finalists,” said Anna Dixon, CTO of binx health. “The Binx io was developed with the healthcare consumer in mind. We wanted to create a solution that would improve the efficiency and productivity of point-of-care testing, simplify infrastructure, processes and procedures, and reduce costs by reducing sample packaging and transportation.
To be chosen as a finalist for the MDEAs is a remarkable achievement. Finalists are selected by a panel of industry experts, including designers, engineers and clinicians. binx’s health io was selected as a finalist in the category “Testing and diagnostic products and systems”.
FDA approved and CLIA exempt from binx health io is the first-ever point-of-care molecular test for the detection of chlamydia and gonorrhea in men and women that provides central laboratory performance results in approximately 30 minutes. The versatile and expandable platform offers point-of-care molecular results, enabling testing and treatment in a single visit.
For patients who seek care in physical locations, and when their priority is speed of outcome, the binx io provides rapid tests for chlamydia and gonorrhea in pharmacies, clinics and in places with a CLIA certificate of waiver, at performance levels equivalent to testing performed in central laboratories. binx io chlamydia and gonorrhea testing platform for asymptomatic and symptomatic patients using urine specimen for males and self-collected or clinician-collected vaginal swab specimen for females. binx io offers the potential to improve health and economic outcomes by enabling one-visit, on-site diagnosis and treatment for chlamydia and gonorrhea.
The category winners and Best in Show recipient will be announced April 7 on mddionline.com. Browse the list of MDEA 2022 finalists here.
About binx health
binx health is a health technology and diagnostics company that makes routine testing easier by enabling access to care where people live, work, study and shop. The Company works with large corporate partners and institutions that have access to large patient populations and have a significant interest in providing or facilitating better healthcare to provide access and enable more streamlined delivery of HIV testing. diagnosis and treatment. Its omnichannel platform includes point of service io platform, which puts central lab-grade testing solutions in the hands of clinicians around the world, and the suite of physician-mediated, medical-guideline-based home sample collection offerings, which bring high-quality testing, population health tools, and seamless digital onboarding capability to those unable or unwilling to visit a clinic.
by binx io is the first-ever FDA-cleared, CLIA-exempt point-of-care tool for the detection of chlamydia and gonorrhea from male and female specimens that provides central lab performance results in approximately 30 minutes. Its platform is highly flexible, easy to use and fast, delivering point-of-care molecular answers with central lab-grade performance and enabling single-visit testing and treatment for the first time. For more information, visit www.binx.com.
